Patents Issued in September 8, 2016
  • Publication number: 20160256407
    Abstract: A transdermal patch suitable for releasing a stimulant such as caffeine for an extended time period utilizes a pressure sensitive acrylic adhesive matrix constituted by an acrylic adhesive having hydroxy groups and an acrylic adhesive without hydroxy, groups, preferably in a respective weight ratio of about 2 to about 3. A suitable caffeine source is caffeine-fortified guarana seed extract, caffeine, a caffeine salt, and the like.
    Type: Application
    Filed: October 10, 2014
    Publication date: September 8, 2016
    Inventors: Servet Buyuktimkin, Nadir Buyuktimkin, James L. Yeager
  • Publication number: 20160256408
    Abstract: Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg/kg body weight of lutein, and at least or about 0.001 mg/kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and/or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 8, 2016
    Inventors: Jayant DESHPANDE, James M. STRINGHAM, Vijaya JUTURU
  • Publication number: 20160256409
    Abstract: A method for protection, treatment and improvement of liver health includes administering a meso-zeaxanthin composition in an effective amount to a subject in need thereof. In particular, methods are described of administering a meso-zexanthin composition to a subject fed with high fat diet (HFD), and studying the effect of meso-zeaxanthin for treatment of fatty liver condition, through evaluation of various parameters such as biochemical indicators, anti-inflammatory markers, and nutritional markers.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 8, 2016
    Inventors: Jayant DESHPANDE, Vijaya JUTURU, Abhijit BHATTACHARYA
  • Publication number: 20160256410
    Abstract: A method of treating a disease state or condition in mammals other than humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck region and/or spine to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream or mousse. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 8, 2016
    Applicant: Afgin Pharma, LLC
    Inventor: Ronald AUNG-DIN
  • Publication number: 20160256411
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 8, 2016
    Applicant: Afgin Pharma, LLC
    Inventor: Ronald AUNG-DIN
  • Publication number: 20160256412
    Abstract: A method of solubilizing curcuminoids is disclosed wherein the method uses polyvinyl pyrrolidone and sodium bis (2-ethylhexyl) sulfosuccinate and the aqueous solubility of curcumin/curcuminoid mixtures is enhanced to more than 10%-15% w/v in water. The present invention also pertains to a curcuminoids composition characterised by not less than 10% w/v, more specifically between 10%-15% w/v aqueous solubility of curcuminoids in water.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 8, 2016
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Publication number: 20160256413
    Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
    Type: Application
    Filed: September 16, 2015
    Publication date: September 8, 2016
    Inventors: Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
  • Publication number: 20160256414
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 8, 2016
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20160256415
    Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from when, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
    Type: Application
    Filed: May 6, 2016
    Publication date: September 8, 2016
    Inventor: John A. McCarty
  • Publication number: 20160256416
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Applicant: Novartis AG
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • Publication number: 20160256417
    Abstract: The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 8, 2016
    Applicant: Drexel University
    Inventor: Sandhya KORTAGERE
  • Publication number: 20160256418
    Abstract: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation comprising a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Formulations comprise a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt thereof; and (b) at least one subcutaneously acceptable inactive ingredient.
    Type: Application
    Filed: May 16, 2016
    Publication date: September 8, 2016
    Inventors: John Daniel DOBAK, Kenneth Walter LOCKE
  • Publication number: 20160256419
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating depigmentation diseases such as vitiligo or leukoctricia. The pharmaceutical composition contains a therapeutically effective amount of fluoxetine.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: Jing SHANG, Sha LIAO, Yu JIN, Xiaoli TIAN, Guorui ZHAO, Jia ZHOU, Qian WANG, Silin PANG
  • Publication number: 20160256420
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: May 16, 2016
    Publication date: September 8, 2016
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20160256421
    Abstract: The present invention relates to a pharmaceutical composition, a functional health food composition, a quasi-drug composition, and a cosmetic composition containing eugenol or a derivative or a pharmaceutically acceptable salt thereof, as an active ingredient, for preventing, treating or alleviating atopic dermatitis. The eugenol or derivative thereof of the present invention has an excellent antipruritic effect on atopic dermatitis, and thus, the eugenol or derivative thereof is a compound which can overcome the side effects of conventionally used therapeutic agents for atopic dermatitis, and displays excellent therapeutic effects without toxicity. Therefore, the eugenol or derivative thereof can be useful as a composition for preventing, treating and alleviating atopic dermatitis.
    Type: Application
    Filed: October 24, 2014
    Publication date: September 8, 2016
    Inventors: Seog Bae OH, Sung Jun JUNG, Ge Hoon CHUNG, Yong Ho KIM, Sang Hoon LEE
  • Publication number: 20160256422
    Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.
    Type: Application
    Filed: September 4, 2013
    Publication date: September 8, 2016
    Applicant: KEMPHYS LTD.
    Inventors: Koichi SHUDO, Kiyoshi SUGIYAMA
  • Publication number: 20160256423
    Abstract: Compositions for increasing the rate of metabolism of alcohol in a human and preventing the symptoms of a hangover comprising amino acids of one or both of L-arginine or L-citrulline; one or more of L-glutamine, L-glutamic acid, glutamine or theanine; and one or both of L-tyrosine or L-phenylalanine. The compositions may also contain other ingredients, such as B vitamins and plant extracts.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 8, 2016
    Inventor: Salim JARROUJ
  • Publication number: 20160256424
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: January 4, 2016
    Publication date: September 8, 2016
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Publication number: 20160256425
    Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 8, 2016
    Inventors: Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
  • Publication number: 20160256426
    Abstract: The present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate. The present invention also refers to the use of said composition for modulating the gut flora of galloanserans.
    Type: Application
    Filed: October 6, 2014
    Publication date: September 8, 2016
    Applicant: Perstorp AB
    Inventors: Filip Van IMMERSEEL, Richard SYGALL, Karolien Van DRIESSCHE, Richard DUCATELLE, Conrad Gerard SCHWARZER
  • Publication number: 20160256427
    Abstract: The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids derivatives thereof, including halogenated esters of both polyunsaturated and monunsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
    Type: Application
    Filed: October 20, 2014
    Publication date: September 8, 2016
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Publication number: 20160256428
    Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
    Type: Application
    Filed: August 18, 2014
    Publication date: September 8, 2016
    Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
  • Publication number: 20160256429
    Abstract: The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
    Type: Application
    Filed: October 8, 2014
    Publication date: September 8, 2016
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE POITIERS, UNIVERSITY OF EXETER
    Inventors: MIROSLAVA SPANOVA, THIERRY FERREIRA, ROMAIN CLEMENT, SHALINEE DHAYAL, NOËL MORGAN
  • Publication number: 20160256430
    Abstract: The present invention is directed to a method for treating skin inflammatory diseases such as dermatitis, psoriasis, and acne, and rosacea, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The method alleviates the symptoms of the disease treated. The active compound can be administered by a systemic route or topical route. Topical administration is a preferred route of administration.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Inventor: Joseph P. ST. LAURENT
  • Publication number: 20160256431
    Abstract: This document provides methods and materials related to treating cancer (e.g. skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g. ABRAXANE®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g. skin cancer) are provided.
    Type: Application
    Filed: February 24, 2016
    Publication date: September 8, 2016
    Inventors: Svetomir N. MARKOVIC, Wendy K. NEVALA
  • Publication number: 20160256432
    Abstract: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 8, 2016
    Inventors: Daniele Piomelli, Giorgio Tarzia, Marco Mor, Andrea Duranti, Andrea Tontini
  • Publication number: 20160256433
    Abstract: The present invention belongs to the field of pharmaceutical industry and relates to an amorphous solid dispersion comprising at least one polymer and dapagliflozin, to a pharmaceutical composition comprising said solid dispersion, to a process for the preparation thereof, and to the solid dispersion and pharmaceutical composition respectively obtainable by said process. Further, the present invention refers to an adsorbate comprising dapagliflozin and to a pharmaceutical composition comprising said adsorbate, as well as to a process for the preparation thereof. Finally, the present invention relates to the solid dispersion, the adsorbate or the pharmaceutical composition for use in the treatment of diseases related to hypoglycemia.
    Type: Application
    Filed: July 22, 2014
    Publication date: September 8, 2016
    Applicant: Sandoz AG
    Inventors: Rok Staric, Sandra Berglez, Jernej GRMAS, Tijana Stanic Ljubin, Rok Grahek, Luka Peternel
  • Publication number: 20160256434
    Abstract: The invention includes methods of treating a subject having hepatitis B viral (HBV) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular STING agonists, thus suppressing HBV replication in hepatocytes. In other embodiments, the method of the invention can be used to treat chronic HBV infections. The invention further provides methods of identifying compounds useful in treating HBV infection in a subject.
    Type: Application
    Filed: October 21, 2014
    Publication date: September 8, 2016
    Inventors: JINHONG CHANG, FANG GUO, TIMOTHY M. BLOCK, JU-TAO GUO
  • Publication number: 20160256435
    Abstract: A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.
    Type: Application
    Filed: May 2, 2016
    Publication date: September 8, 2016
    Inventor: Stephen C. Perry
  • Publication number: 20160256436
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 8, 2016
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa
  • Publication number: 20160256437
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Application
    Filed: March 30, 2016
    Publication date: September 8, 2016
    Inventors: Ellen SCHMIDT, Johan AREBERG
  • Publication number: 20160256438
    Abstract: Provided are N-alkyl imidazole 2-aldoximes, including cationic imidazolium and uncharged tertiary imidazole aldoximes, and compositions and methods for making and using them, including methods for reactivating human butyrylcholinesterase (hBChE) or acetylcholinesterase (hAChE) inhibited by organophosphate (OP). By administration of a composition of the invention, the inactive or conjugated hBChE-OP or hAChE-OP is reactivated and the catalytic cycle of turnover and inactivation of the OP is completed; and in alternative embodiments, secondary mechanisms of reversible protection of hBChE and hAChE from irreversible inactivation by OPs and reactivation of tissue AChE also contribute to overall efficacy.
    Type: Application
    Filed: October 15, 2014
    Publication date: September 8, 2016
    Inventors: Palmer TAYLOR, Zoran RADIC, Valery FOKIN
  • Publication number: 20160256439
    Abstract: Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject. The pharmaceutical composition includes phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones formulated for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 8, 2016
    Applicant: Ohio University
    Inventors: Kelly D. McCall, Frank L. Schwartz, Douglas J. Goetz, Ramiro Malgor
  • Publication number: 20160256440
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
    Type: Application
    Filed: May 16, 2016
    Publication date: September 8, 2016
    Inventors: Kevin Michael Short, Son Minh Pham, David Charles Williams, Somalee Datta
  • Publication number: 20160256441
    Abstract: The present disclosure concerns uses for isoxazole compounds or salts or analogs thereof for the treatment of wounds. The present disclosure also concerns devices for delivering a isoxazole compound or salts or an analogs thereof to a wound site.
    Type: Application
    Filed: October 16, 2014
    Publication date: September 8, 2016
    Applicant: The Board of Regents of the University of Texas Sy stem
    Inventors: Eric M. SMALL, Eric N. OLSON
  • Publication number: 20160256442
    Abstract: This invention relates to long-acting injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a poloxamer, and a co-solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the long-acting injectable formulations of the invention to the animal in need thereof.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 8, 2016
    Applicant: MERIAL, INC.
    Inventors: Susan Mancini Cady, Peter Cheifetz, Izabela Galeska
  • Publication number: 20160256443
    Abstract: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
    Type: Application
    Filed: December 8, 2015
    Publication date: September 8, 2016
    Applicant: Transderm, Inc.
    Inventors: Roger Louis Kaspar, Robyn Patricia Hickerson
  • Publication number: 20160256444
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 8, 2016
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20160256445
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 8, 2016
    Inventors: Saleem Ahmad, Lidet A. Negash
  • Publication number: 20160256446
    Abstract: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Type: Application
    Filed: May 16, 2016
    Publication date: September 8, 2016
    Inventor: Daniel J. Rader
  • Publication number: 20160256447
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: October 7, 2015
    Publication date: September 8, 2016
    Inventors: Magdalene M. Moran, Jayhong A. Chong, Christopher Fanger, Amy Ripka, Glenn R. Larsen, Xiaoguang Zhen, Dennis John Underwood, Manfred Weigele
  • Publication number: 20160256448
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Kenneth W. BAIR, Torsten HERBERTZ, Goss S. KAUFFMAN, Katherine J. KAYSER-BRICKER, George P. LUKE, Matthew W. MARTIN, David S. MILLAN, Shawn E.R. SCHILLER, Adam C. TALBOT
  • Publication number: 20160256449
    Abstract: The disclosure relates to the compound 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, intended for the treatment of Alzheimer's disease and other types of dementia.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 8, 2016
    Inventors: Sophie CLAUDEL, Jeanne STEMMELIN, Pascal BARNEOUD, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Jeremy PRATT
  • Publication number: 20160256450
    Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: March 10, 2016
    Publication date: September 8, 2016
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20160256451
    Abstract: The present invention relates to a pharmaceutical composition comprising a ?-receptor antagonist as an active substance, wherein the antagonist is prepared in an extended release formulation. The composition is intended for the treatment of patients with opioid-induced constipation, wherein the dosage of the ?-receptor agonist is independent of the opioid dosage. The preferred dosage of the ?-receptor antagonist of the composition is equivalent to a daily dosage of 20-70 mg naloxone.
    Type: Application
    Filed: August 17, 2015
    Publication date: September 8, 2016
    Inventors: Helene Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
  • Publication number: 20160256452
    Abstract: The present invention relates to a composition comprising an opioid receptor antagonist in an extended release formulation for use in treating a patient with severe constipation characterised by a defined whole gut transit time.
    Type: Application
    Filed: August 17, 2015
    Publication date: September 8, 2016
    Inventors: Helene Rey, Marc Fischer, Isabelle Golfier, Christian Holl
  • Publication number: 20160256453
    Abstract: The present invention relates to a pharmaceutical composition comprising an opioid receptor antagonist, or a derivative or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. The composition that is suitable for an administration period of at least twelve-hours for the treatment of severe opioid-induced constipation in patients receiving a daily dosage of opioid equivalent to at least 80 mg of morphine.
    Type: Application
    Filed: August 17, 2015
    Publication date: September 8, 2016
    Inventors: Helene Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
  • Publication number: 20160256454
    Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is from about 4×104 moles to about 2.0×10?3 moles.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Inventors: Chandrashekar Giliyar, Satish Kumar Nachaegari, Chidambaram Nachiappan, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Publication number: 20160256455
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 8, 2016
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Publication number: 20160256456
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 8, 2016
    Inventors: Frank S. CARUSO, Huai-Hung KAO